Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan.
Gastrointest Endosc. 2018 Oct;88(4):637-646. doi: 10.1016/j.gie.2018.06.033. Epub 2018 Jul 6.
Salvage endoscopic submucosal dissection (ESD) after chemoradiotherapy can be technically difficult as a result of radiation-induced fibrosis. We aimed to evaluate the technical feasibility of ESD for local failure after chemoradiotherapy for esophageal squamous cell carcinoma (ESCC) and for other primary lesions within the irradiation field.
Consecutive patients treated with ESD for superficial ESCC between December 2009 and May 2017 were investigated retrospectively and stratified into group A (33 patients, 35 lesions; local failure at the primary site after chemoradiotherapy), group B (25 patients, 34 lesions; second primary lesions within the irradiation field), and group C (550 patients, 596 lesions; radiotherapy-naïve superficial ESCC). We evaluated procedural success rate, en bloc resection rate, 1-year local relapse-free survival (LRFS) rate, procedure time, and incidence of major adverse events.
The rates of procedural success and en bloc resection, respectively, were significantly lower in group A (89%, 86%) than in groups B (100%, 100%) and C (100%, 98%). The 1-year LRFS rates were 86%, 100%, and 99% in groups A, B, and C, respectively, and significantly lower in group A than in group C. Serious adverse events including perforation were not observed in groups A and B; perforation occurred only in group C (2.8%).
ESD is technically feasible in patients with local failure, especially as initial salvage treatment and as treatment for second primary lesions within the irradiation field.
由于放射诱导纤维化,放化疗后挽救性内镜黏膜下剥离术(ESD)可能在技术上具有挑战性。我们旨在评估 ESD 治疗食管鳞状细胞癌(ESCC)放化疗后局部复发和照射野内其他原发性病变的技术可行性。
回顾性分析 2009 年 12 月至 2017 年 5 月期间接受 ESD 治疗的浅表性 ESCC 连续患者,并分为 A 组(33 例,35 处病变;放化疗后原发部位局部复发)、B 组(25 例,34 处病变;照射野内第二原发性病变)和 C 组(550 例,596 处病变;未接受放疗的浅表性 ESCC)。我们评估了操作成功率、整块切除率、1 年局部无复发生存率(LRFS)、操作时间和主要不良事件发生率。
A 组的操作成功率(89%)和整块切除率(86%)显著低于 B 组(100%,100%)和 C 组(100%,98%)。A、B、C 组 1 年 LRFS 率分别为 86%、100%和 99%,A 组显著低于 C 组。A、B 组未观察到严重不良事件(包括穿孔);仅在 C 组发生穿孔(2.8%)。
ESD 在局部复发患者中具有技术可行性,尤其是作为初始挽救性治疗和照射野内第二原发性病变的治疗方法。